Co-Authors
This is a "connection" page, showing publications co-authored by MERRICK I ROSS and RICHARD E ROYAL.
Connection Strength
0.806
-
Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clin Cancer Res. 2020 04 15; 26(8):1886-1895.
Score: 0.179
-
Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Mod Pathol. 2020 03; 33(3):496-513.
Score: 0.043
-
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1941.
Score: 0.041
-
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1942.
Score: 0.041
-
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
Score: 0.041
-
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428.
Score: 0.040
-
Circulating Tumor Cells in Stage IV Melanoma Patients. J Am Coll Surg. 2018 07; 227(1):116-124.
Score: 0.040
-
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
Score: 0.039
-
Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. J Clin Oncol. 2016 05 20; 34(15):1741-7.
Score: 0.034
-
Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. J Invest Dermatol. 2015 Sep; 135(9):2266-2272.
Score: 0.032
-
C-reactive protein as a marker of melanoma progression. J Clin Oncol. 2015 Apr 20; 33(12):1389-96.
Score: 0.032
-
The relationship between blood IL-12p40 level and melanoma progression. Int J Cancer. 2015 Apr 15; 136(8):1874-80.
Score: 0.031
-
A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion. Ann Surg Oncol. 2015 Jan; 22(1):287-94.
Score: 0.031
-
Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg. 2014 Jun; 259(6):1215-22.
Score: 0.030
-
Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. Melanoma Res. 2013 Aug; 23(4):290-7.
Score: 0.028
-
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012 Dec 15; 18(24):6758-70.
Score: 0.027
-
Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. Melanoma Res. 2012 Oct; 22(5):376-85.
Score: 0.027
-
Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol. 2011 Mar 20; 29(9):1210-5.
Score: 0.024
-
Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011 Jan 19; 103(2):129-42.
Score: 0.024
-
Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. Ann Surg Oncol. 2010 Oct; 17(10):2764-72.
Score: 0.023